Gemcitabine HCL Market (Type: Branded and Generic; Application: Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-small Cell Lung Carcinoma, and Others)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Gemcitabine HCL market size was estimated at USD 935.1 million in 2021 and is expected to surpass around USD 1.85 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 8.10% during the forecast period 2022 to 2030.

Gemcitabine is widely used as an antitumor agent in research labs and clinics. It is an antimetabolite and antineoplastic agent. Gemzar [gemcitabine hydrochloride (HCL)] is a nucleoside metabolic inhibitor that exhibits antitumor activity. It is soluble in water, mildly soluble in methanol, and insoluble in polar organic solvents and ethanol. In sterile form, it is administered intravenously. Vials contain either 200 mg or 1 g, 2 g, and 4 g of Gemzar. Increased awareness about cancer and patient support programs is also expected to propel the gemcitabine HCl market size from 2022 to 2031. For instance, Pancreatic Cancer Action Network hosts Pancreatic Cancer Awareness Month in November, every year, in order to donate and participate in fundraising and support legislation for research and other activities.

Report Scope of the Gemcitabine HCL Market

Rise in Cancer Awareness and Patient Support Programs to Drive Demand for Gemcitabine HCL

Governments in developed and developing countries are conducting awareness campaigns in order to reduce mortality and morbidity rates and encourage people to go for early cancer diagnosis. This is expected to increase awareness about cancer diagnosis and treatment. For instance, Public Health England, an executive agency of the Department of Health in the U.K., started “Be Clear on Cancer” campaign, which aims to improve the rate of early cancer diagnosis. Several companies have started Patient Support Programs (PSPs) to reduce the cost of treatment. For instance, Roche's Blue Tree Program offers support to cancer patients during their treatment journey.

Reformulation Strategies Used by Companies to Preserve or Establish Market Dominance

R&D strategies in the gemcitabine drug market for the last few years have been focusing primarily on improvement in treatment delivery and combination therapy. High unmet needs in this area and poor efficacy of current treatments in pancreatic cancer, which are mostly chemotherapies, have prompted developers to explore improved versions of branded gemcitabine agents.

NuCana Biomed’s Acelarin (NUC-1031), a reformulation of gemcitabine, is in late-stage clinical trial and has been engineered to overcome resistance mechanisms associated with the original drug. In 2019, Sun Pharma launched ready-to-infuse INFUGEM (gemcitabine in sodium chloride injection) in the U.S. INFUGEM, the first chemotherapy product that comes in a premixed, ready-to-infuse formulation, was approved by the U.S. Food and Drug Administration (FDA) in July 2018, in combination with other drugs, for the treatment of breast, ovarian, non-small cell lung cancers, and as a single agent to treat pancreatic cancer.

Efficacy and Low Cost Augmenting Demand for Generic Drugs

In terms of type, the global gemcitabine HCl market has been bifurcated into branded and generic. The generic segment held a dominant share of the market in 2021. The trend is projected to continue during the forecast period. This can be ascribed to low cost and efficacy of generic drugs and rise in number of cancer patients, which have led to an increase in demand for these products. Gemcitabine in combination with nab-paclitaxel has been reported to prolong survival in patients with metastatic pancreatic cancer.

Rise in Patient Population with Pancreatic Cancer

Based on application, the global gemcitabine HCl market has been classified as pancreatic cancer, breast cancer, ovarian cancer, non-small cell lung carcinoma (NSCLC), and others. The pancreatic cancer segment is projected to dominate the global market during the forecast period, accounting for the major share of the market by 2031. Gemcitabine is the first line drug for the treatment of pancreatic cancer. Increase in demand for drugs to treat pancreatic cancer is expected to drive the segment.

Government Support for Private Players to Drive Hospitals Segment

In terms of end-user, the global gemcitabine HCl market has been divided as hospitals, cancer centers, and others. The hospitals segment is anticipated to dominate the global market during the forecast period. The segment is projected to account for a significant market share in 2030. The hospital infrastructure in emerging economies is developing at a significant pace, as several regional and national governments (for instance, Saudi Arabia) are encouraging private players to enter the healthcare services sector. Moreover, a large number of patients were treated in hospitals in the U.S. and Europe in 2021.

Regional Outlook of Global Gemcitabine HCL Market

North America dominated the global gemcitabine HCl market, with more than 31% share in 2021. High adoption of generic drugs in the U.S., increasing approvals for new cancer drugs by the U.S. FDA, and rise in cancer treatments options in the U.S. and Canada contributed to North America's large market share.

Asia Pacific is also poised to register significant growth during the forecast period owing to large patient pool, increase in the incidence of cancer, aging population, rise in demand for generic cancer drugs, and export of generic drugs to Europe and North America.

Analysis of Key Players in Global Gemcitabine HCL Market

The global gemcitabine HCl market is fragmented, with the presence of international and local players. Players are focused on adopting strategies such as acquisition & collaboration, geographic expansion, expansion of distribution channels, and R&D to enhance their share in the global gemcitabine HCl market. Key players operating in the global gemcitabine HCl market are Accord Healthcare, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Mylan N.V., Fresenius SE & Co. KGaA, Pfizer, Inc., Eli Lilly and Company, Ingenus Pharmaceuticals, LLC., Cornerstone Pharmaceuticals, Inc. ADC Therapeutics SA, and Hikma Pharmaceuticals plc.

Key Developments in Global Gemcitabine HCL Market

• In August 2022, Wungki Park, an oncologist at Memorial Sloan Kettering Cancer Center, announced the phase 2 clinical trial of chimeric monoclonal antibody, zolbetuximab, in combination with gemcitabine and nab-paclitaxel vs gemcitabine and nab-paclitaxel alone as a frontline treatment for patients with metastatic pancreatic cancer
• In August 2022, Cornerstone Pharmaceuticals, Inc. announced the completion of its phase 1b clinical trial of CPI-613 (devimistat) in combination with gemcitabine and cisplatin for the treatment of advanced unresectable biliary tract cancer
• In July 2022, ADC Therapeutics SA announced that its first patient had been dosed in the phase 1b clinical trial evaluating mipasetamab uzoptirine, targeting the AXL receptor tyrosine kinase as a single agent, and in combination with gemcitabine in patients with selected advanced solid tumors
• In June 2021, Panbela Therapeutics, Inc. had presented interim clinical data from its phase 1b study of SBP-101, with gemcitabine and nab-paclitaxel in patients with metastatic Pancreatic Ductal Adenocarcinoma (PDA), at the American Society of Clinical Oncology (ASCO)
• In November 2020, the U.S. FDA approved Pembrolizumab plus chemotherapy (including gemcitabine) as treatment for patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1

Some of the prominent players in the Gemcitabine HCL Market include:

• Accord Healthcare
• Teva Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• Mylan N.V.
• Fresenius SE & Co. KGaA
• Pfizer, Inc.
• Eli Lilly and Company
• Ingenus Pharmaceuticals, LLC.
• Cornerstone Pharmaceuticals, Inc.
• ADC Therapeutics SA
• Hikma Pharmaceuticals pl

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Gemcitabine HCL market

• Type
• Branded
• Generic
• Application
• Pancreatic Cancer
• Breast Cancer
• Ovarian Cancer
• Non-small Cell Lung Carcinoma (NSCLC)
• Others
• End-user
• Hospitals
• Cancer Centers
• Others

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Gemcitabine HCL industry analysis from 2022 to 2030 to identify the prevailing Gemcitabine HCL industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Gemcitabine HCL industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Gemcitabine HCL industry trends, key players, market segments, application areas, and market growth strategies.